SV

Street Verdict

Analyst Scorecard

A record of what ICICI Securities Analysis said publicly, with the source. Not advice.

Pending — not yet graded
“Upgraded GlaxoSmithKline Pharmaceuticals to 'Add' from 'Hold' with a revised target price of ₹2,250 (previously ₹2,550), based on 38x FY26E earnings. The brokerage expects GSK to achieve an earnings CAGR of 15.3% over FY24-27E, driven by a revenue CAGR of 9.1%, and sees improved RoE and RoCE due to an asset-light and cash-rich balance sheet. Key risks include more products under price control and delayed new product launches.”

ICICI Securities Analysis’s track record (trackable calls only): 265 graded calls · 95% CI 41–52%

GlaxoSmithKline Pharmaceuticals Ltd.BullishCalled 19 Feb 2025
Verdict:PENDING

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹2,250, as stated.

Window: 12 months, the default when no time frame is stated.

Window still open: no verdict until a close reaches a level or the window ends.

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Tracking GlaxoSmithKline Pharmaceuticals Ltd. since this call

1-year tracking window
Read the original articleSee ICICI Securities Analysis’s full track record